Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 16, Issue 1, 2016, Pages 5-11

  Phipps, Colin ^a,b   Chen, Yunxin ^a   Tan, Daryl ^a,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c RAFFLES HOSPITAL   (Singapore)

Author keywords

Chemotherapy; Hepatitis B reactivation; Immunosuppression; Liver failure; Lymphoma

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BELINOSTAT; BORTEZOMIB; CORTICOSTEROID; IBRUTINIB; IDELALISIB; MOGAMULIZUMAB; RITUXIMAB; ROMIDEPSIN; VORINOSTAT; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CORTICOSTEROID THERAPY; HEPATITIS B; HISTORY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS REACTIVATION; VIRUS REPLICATION; ADVERSE EFFECTS; BLOOD; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; MALE; METABOLISM; PHYSIOLOGY; VIRUS ACTIVATION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BORTEZOMIB; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MALE; RITUXIMAB; VIRUS ACTIVATION;

EID: 84952034848     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.11.009     Document Type: Review

References (50)

1. R. Thimme, S. Wieland, C. Steiger, and et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection J Virol 77 2003 68 76
2. T.L. Fong, A.M. Di Bisceglie, R. Biswas, and et al. High levels of viral replication during acute hepatitis B infection predict progression to chronicity J Med Virol 43 1994 155 158
3. L.G. Guidotti, R. Rochford, J. Chung, and et al. Viral clearance without destruction of infected cells during acute HBV infection Science 284 1999 825 829
4. K.R. Karlmark, H.E. Wasmuth, C. Trautwein, and et al. Chemokine-directed immune cell infiltration in acute and chronic liver disease Expert Rev Gastroenterol Hepatol 2 2008 233 242
5. M. Gilliet, and Y.J. Liu Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells Hum Immunol 63 2002 1149 1155
6. M.L. Op den Brouw, R.S. Binda, M.H. van Roosmalen, and et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus Immunology 126 2009 280 289
7. M. Hosel, M. Quasdorff, K. Wiegmann, and et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection Hepatology 50 2009 1773 1782
8. K. Kimura, K. Kakimi, S. Wieland, and et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice J Virol 76 2002 10702 10707
9. C. Wei, C. Ni, T. Song, and et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein J Immunol 185 2010 1158 1168
10. M. Kumar, S.Y. Jung, A.J. Hodgson, and et al. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon J Virol 85 2011 987 995
11. G. Raimondo, T. Pollicino, I. Cacciola, and et al. Occult hepatitis B virus infection J Hepatol 46 2007 160 170
12. H.L. Chan, A. Thompson, M. Martinot-Peignoux, and et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report J Hepatol 55 2011 1121 1131
13. J.R. Wands, C.M. Chura, F.J. Roll, and et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders Gastroenterology 68 1975 105 112
14. A.S. Lok, R.H. Liang, E.K. Chiu, and et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 1991 182 188
15. K. Kumagai, T. Takagi, S. Nakamura, and et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan Ann Oncol 8 suppl 1 1997 107 109
16. R.G. Hanson, M.G. Peters, and J.H. Hoofnagle Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis Hepatology 6 1986 173 179
17. G.H. Scullard, C.I. Smith, T.C. Merigan, and et al. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B Gastroenterology 81 1981 987 991
18. E. Sagnelli, G. Manzillo, G. Maio, and et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis Lancet 2 1980 395 397
19. R. Tur-Kaspa, Y. Shaul, D.D. Moore, and et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer Virology 167 1988 630 633
20. A.L. Cheng, C.A. Hsiung, I.J. Su, and et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma Hepatology 37 2003 1320 1328
21. X. Xu, Q. Shang, X. Chen, and et al. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients Cell Mol Immunol 12 2015 309 316
22. I. Dervite, D. Hober, and P. Morel Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab N Engl J Med 344 2001 68 69
23. T.H. Westhoff, F. Jochimsen, A. Schmittel, and et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy Blood 102 2003 1930
24. W. Yeo, T.C. Chan, N.W. Leung, and et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 2009 605 611
25. W.K. Seto, T.S. Chan, Y.Y. Hwang, and et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study J Clin Oncol 32 2014 3736 3743
26. K. Matsue, S. Kimura, Y. Takanashi, and et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma Cancer 116 2010 4769 4776
27. C. Hsu, H.H. Tsou, S.J. Lin, and et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study Hepatology 59 2014 2092 2100
28. E. Iannitto, V. Minardi, G. Calvaruso, and et al. Hepatitis B virus reactivation and alemtuzumab therapy Eur J Haematol 74 2005 254 258
29. A. Cortelezzi, M. Vigano, V.R. Zilioli, and et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H J Clin Virol 35 2006 467 469
30. S.E. Moses, Z.Y. Lim, M. Sudhanva, and et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab J Med Virol 78 2006 1560 1563
31. Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res E pub 15 April 2015
32. N. Nakano, S. Kusumoto, Y. Tanaka, and et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab Hepatol Res 44 2014 354 357
33. H. Totani, S. Kusumoto, T. Ishida, and et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy Int J Hematol 101 2015 398 404
34. H. Yang, Z. Cao, Z. Wang, and et al. [Hepatitis B virus reactivation induced by brentuximab vedotin in the treatment of Hodgkin lymphoma: a case report and literature review] Zhonghua Xue Ye Xue Za Zhi 35 2014 949 950
35. J. Li, B. Huang, Y. Li, and et al. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant Leuk Lymphoma 56 2015 1710 1717
36. J.D. Yang, M. Girotra, A. Restrepo, and et al. Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance Ann Hepatol 13 2014 461 465
37. T. Pollicino, L. Belloni, G. Raffa, and et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones Gastroenterology 130 2006 823 837
38. W.Y. Chen, E.C. Bailey, S.L. McCune, and et al. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase Proc Natl Acad Sci U S A 94 1997 5798 5803
39. D. Ritchie, R.L. Piekarz, P. Blombery, and et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report Haematologica 94 2009 1618 1622
40. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
41. J.P. Hwang, M.R. Somerfield, D.E. Alston-Johnson, and et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update J Clin Oncol 33 2015 2212 2220
42. R.P. Perrillo, R. Gish, and Y.T. Falck-Ytter American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy Gastroenterology 148 2015 221 244
43. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
44. G.K. Lau, H.H. Yiu, D.Y. Fong, and et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy Gastroenterology 125 2003 1742 1749
45. C. Hsu, C.A. Hsiung, I.J. Su, and et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial Hepatology 47 2008 844 853
46. P. Marcellin, E. Gane, M. Buti, and et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
47. D.J. Tenney, R.E. Rose, C.J. Baldick, and et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
48. H. Huang, X. Li, J. Zhu, and et al. Entecavir vs. lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial JAMA 312 2014 2521 2530
49. J.P. Hwang, and A.S. Lok Management of patients with hepatitis B who require immunosuppressive therapy Nat Rev Gastroenterol Hepatol 11 2014 209 219
50. Y.H. Huang, L.T. Hsiao, Y.C. Hong, and et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B J Clin Oncol 31 2013 2765 2772